Amgen Shows Repatha Reduces Death Risk in High-Risk Patients
Thousand Oaks, Calif. – August 31, 2026 Amgen announced new Phase 3 findings showing that Repatha® (evolocumab) reduced the...
Myocardial Infarction
Advertisement
Advertisement
